FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898093510> ?p ?o ?g. }

• W2898093510 endingPage "viii672" @default.
• W2898093510 startingPage "viii672" @default.
• W2898093510 abstract "Background: PSC, with epithelial (E) and sarcomatoid (S) components, is an aggressive type of non-small cell lung cancer (NSCLC). Molecularly-targeted therapy and anti-PD-1/PD-L1 immunotherapy (IO) have changed the treatment paradigm of NSCLC. The majority of PD-L1 negative NSCLC express alternative immune checkpoints (IC): B7H3, B7x and HHLA2. There is limited information on the profile of these IC and their association with driver mutations (mut) in PSC. Methods: IC expression was examined in tissue microarrays of 41 PSC by IHC. PD-L1 positive cases were defined as PD-L1≥ 1% in tumor cells. B7X, HHLA2, and B7H3 were scored for intensity and percent staining (positive cases were intensity of 1,2 or 3). Percent of TILs was scored in 5% increments. In this cohort, 69% of patients (pts) were smokers, 20% (8 pts) had MET ex 14 skipping and 15% (6 pts) harbored KRAS mut, without cases of EGFR, BRAF or ALK fusion. Results: PD-L1 was positive in 75% (27/36) with most (78%, 21/27) expressing PD-L1 ≥50%. Only 33% (9/27) had PD-L1 expression in both E and S components, and the expression between E and S was statistically different (P < 0.007). There was a trend of shorter overall survival in pts whose tumors were positive for PD-L1 (671 vs. 985 days). The expression of B7x, B7H3, and HHLA2 was positive in 67%, 72% and 94% of cases. All cases expressed at least one IC with 42% (15/36) being quadruple positive. 69% of cases had tumor-infiltrating lymphocyte (TIL) density≥10%. Among 8 pts with MET mut, the frequency of PD-L1, B7x, B7H3 and HHLA2 positive cases were 100% (6 with PD-L1 ≥50%), 75%, 75% and 100%. In 6 pts with KRAS mut, the rate of PD-L1, B7x, B7H3 and HHLA2 positive cases were 83% (2 with PD-L1 ≥50%), 67%, 75% and 83%. The median H-score (intensity x percent) of HHLA2 was significantly different between the METex14 vs. wildtype in both E (P = 0.0001) and S components (P = 0.01). Conclusions: In our PSC series, PD-L1 (≥ 50%) was expressed in the majority of cases and all cases expressed at least one IC. Along with wide TIL distribution, our findings favor exploration of IO in PSC. The enrichment of METex14 and potential interplay between MET and PD-L1/HHLA2 in PSC suggest that future combination studies with MET inhibitor and IO are warranted. Legal entity responsible for the study: Montefiore Medical Center. Funding: Has not received any funding. Disclosure: X. Zang: Inventor on patent number US 9447186 B2 which covers the topic of anti-B7x cancer immunotherapy; Inventor on two pending patents which cover the topic of HHLA2-directed immunotherapy. All other authors have declared no conflicts of interest." @default.
• W2898093510 created "2018-11-02" @default.
• W2898093510 creator A5002110784 @default.
• W2898093510 creator A5003136678 @default.
• W2898093510 creator A5022388453 @default.
• W2898093510 creator A5039297373 @default.
• W2898093510 creator A5040339666 @default.
• W2898093510 creator A5061376402 @default.
• W2898093510 creator A5063025231 @default.
• W2898093510 creator A5081356537 @default.
• W2898093510 date "2018-10-01" @default.
• W2898093510 modified "2023-10-18" @default.
• W2898093510 title "Differential expression of immune checkpoints (PD-L1, HHLA2, B7x and B7H3) and their association with driver mutations in pulmonary sarcomatoid carcinoma (PSC)" @default.
• W2898093510 doi "https://doi.org/10.1093/annonc/mdy304.005" @default.
• W2898093510 hasPublicationYear "2018" @default.
• W2898093510 type Work @default.
• W2898093510 sameAs 2898093510 @default.
• W2898093510 citedByCount "0" @default.
• W2898093510 crossrefType "journal-article" @default.
• W2898093510 hasAuthorship W2898093510A5002110784 @default.
• W2898093510 hasAuthorship W2898093510A5003136678 @default.
• W2898093510 hasAuthorship W2898093510A5022388453 @default.
• W2898093510 hasAuthorship W2898093510A5039297373 @default.
• W2898093510 hasAuthorship W2898093510A5040339666 @default.
• W2898093510 hasAuthorship W2898093510A5061376402 @default.
• W2898093510 hasAuthorship W2898093510A5063025231 @default.
• W2898093510 hasAuthorship W2898093510A5081356537 @default.
• W2898093510 hasBestOaLocation W28980935101 @default.
• W2898093510 hasConcept C121608353 @default.
• W2898093510 hasConcept C126322002 @default.
• W2898093510 hasConcept C143998085 @default.
• W2898093510 hasConcept C193270364 @default.
• W2898093510 hasConcept C204232928 @default.
• W2898093510 hasConcept C2776256026 @default.
• W2898093510 hasConcept C2777701055 @default.
• W2898093510 hasConcept C2780851360 @default.
• W2898093510 hasConcept C2781053074 @default.
• W2898093510 hasConcept C2781187634 @default.
• W2898093510 hasConcept C502942594 @default.
• W2898093510 hasConcept C526805850 @default.
• W2898093510 hasConcept C71924100 @default.
• W2898093510 hasConceptScore W2898093510C121608353 @default.
• W2898093510 hasConceptScore W2898093510C126322002 @default.
• W2898093510 hasConceptScore W2898093510C143998085 @default.
• W2898093510 hasConceptScore W2898093510C193270364 @default.
• W2898093510 hasConceptScore W2898093510C204232928 @default.
• W2898093510 hasConceptScore W2898093510C2776256026 @default.
• W2898093510 hasConceptScore W2898093510C2777701055 @default.
• W2898093510 hasConceptScore W2898093510C2780851360 @default.
• W2898093510 hasConceptScore W2898093510C2781053074 @default.
• W2898093510 hasConceptScore W2898093510C2781187634 @default.
• W2898093510 hasConceptScore W2898093510C502942594 @default.
• W2898093510 hasConceptScore W2898093510C526805850 @default.
• W2898093510 hasConceptScore W2898093510C71924100 @default.
• W2898093510 hasLocation W28980935101 @default.
• W2898093510 hasOpenAccess W2898093510 @default.
• W2898093510 hasPrimaryLocation W28980935101 @default.
• W2898093510 hasRelatedWork W1533135684 @default.
• W2898093510 hasRelatedWork W2786497694 @default.
• W2898093510 hasRelatedWork W2980533584 @default.
• W2898093510 hasRelatedWork W3083489679 @default.
• W2898093510 hasRelatedWork W3157248895 @default.
• W2898093510 hasRelatedWork W3217115064 @default.
• W2898093510 hasRelatedWork W4220781313 @default.
• W2898093510 hasRelatedWork W4313430032 @default.
• W2898093510 hasRelatedWork W4323664831 @default.
• W2898093510 hasRelatedWork W2553145634 @default.
• W2898093510 hasVolume "29" @default.
• W2898093510 isParatext "false" @default.
• W2898093510 isRetracted "false" @default.
• W2898093510 magId "2898093510" @default.
• W2898093510 workType "article" @default.